CommercialCoverageLow impact
Retail Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Hematology, Pediatrics·Pharmacy
Effective date
Jan 7, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated criteria for the drug Alhemo (hemophilia treatment) to allow use for members without inhibitors and added restrictions against combining with Hympavzi or Qfitlia. This affects Essential Formulary coverage for hemophilia patients.
Action Required
By January 7, 2026: Review hemophilia patients currently prescribed Alhemo to ensure they meet updated criteria (no inhibitors per label, not using with Hympavzi or Qfitlia). Update prior authorization requests to reflect new criteria. Notify providers treating hemophilia patients of the combination restrictions.